Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker price is limiting access to patients and siphoning money away from Medicaid, according ...
Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
It's one of the top healthcare stocks in my portfolio. If I didn't already own this biotech stock, I wouldn't hesitate to buy ...
Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
The drug is already approved to treat non-metastatic ... including Johnson & Johnson's Erleada (apalutamide) and Pfizer/Astellas' Xtandi (enzalutamide), although analysts have suggested that ...
The drug was earlier being developed for Duchenne ... that looked at the combination of FG-3246 with Pfizer/Astellas' Xtandi (enzalutamide) in mCRPC and set up a phase 2 programme.
The biotech industry is ripe with great investment opportunities due to technological advancements such as artificial ...
Stocktwits on MSN2d
Super Micro’s Stellar Rally Continues Unabated, AI Server Maker Becomes Best-Performing S&P 500 Stock In 2025Super Micro Computer, Inc. (SMCI) stock is on an extended bull run and has more than doubled in 2025. The stock is now the ...
The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback